ERBB2 and neoplasm: To determine the tumor-targeting ability of H2.1MS1 spheres in vivo, Her2-overexpressing (Her2(+)) and Her2-negative (Her2(−)) mouse breast tumor cells (D2F2E2/LUC and D2F2/LUC cell lines, respectively) were used in this study.